These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
93 related articles for article (PubMed ID: 3324526)
41. Effects of verapamil on haemodynamic function and myocardial metabolism in patients with hypertrophic cardiomyopathy. Wilmshurst PT; Thompson DS; Juul SM; Jenkins BS; Webb-Peploe MM Br Heart J; 1986 Dec; 56(6):544-53. PubMed ID: 3801246 [TBL] [Abstract][Full Text] [Related]
42. Long-term effect of verapamil in hypertrophic cardiomyopathy. Hasin Y; Lewis BS; Lewis N; Weiss AT; Gotsman MS Int J Cardiol; 1982; 1(3-4):243-51. PubMed ID: 6807854 [TBL] [Abstract][Full Text] [Related]
43. Changes of the degree of hypertrophy in hypertrophic obstructive cardiomyopathy under medical and surgical treatment. Curtius JM; Stoecker J; Loesse B; Welslau R; Scholz D Cardiology; 1989; 76(4):255-63. PubMed ID: 2529965 [TBL] [Abstract][Full Text] [Related]
44. Evolution of the electrocardiographic changes in patients with hypertrophic cardiomyopathy. Tendera M; Poloński L; Wodniecki J; Kardaszewicz P Clin Cardiol; 1991 Nov; 14(11):891-6. PubMed ID: 1764825 [TBL] [Abstract][Full Text] [Related]
45. Propranolol for severe infantile hemangiomas: follow-up report. Sans V; de la Roque ED; Berge J; Grenier N; Boralevi F; Mazereeuw-Hautier J; Lipsker D; Dupuis E; Ezzedine K; Vergnes P; Taïeb A; Léauté-Labrèze C Pediatrics; 2009 Sep; 124(3):e423-31. PubMed ID: 19706583 [TBL] [Abstract][Full Text] [Related]
47. A double-blind, placebo-controlled crossover trial of nadolol and verapamil in mild and moderately symptomatic hypertrophic cardiomyopathy. Gilligan DM; Chan WL; Joshi J; Clarke P; Fletcher A; Krikler S; Oakley CM J Am Coll Cardiol; 1993 Jun; 21(7):1672-9. PubMed ID: 8496536 [TBL] [Abstract][Full Text] [Related]
48. Verapamil therapy: a new approach to the pharmacologic treatment of hypertrophic cardiomyopathy. II. Effects on exercise capacity and symptomatic status. Rosing DR; Kent KM; Maron BJ; Epstein SE Circulation; 1979 Dec; 60(6):1208-13. PubMed ID: 574067 [No Abstract] [Full Text] [Related]
54. Evaluation of the ocular safety of verapamil. Scheimpflug photography with densitometric image analysis of lens transparency in patients with hypertrophic cardiomyopathy subjected to long-term therapy with high doses of verapamil. Hockwin O; Dragomirescu V; Laser H; Ohrloff C; Kozamanoglu K; Kremer F Ophthalmic Res; 1984; 16(5):264-75. PubMed ID: 6541330 [TBL] [Abstract][Full Text] [Related]
55. Long-term follow-up of medical versus surgical therapy for hypertrophic cardiomyopathy: a retrospective study. Seiler C; Hess OM; Schoenbeck M; Turina J; Jenni R; Turina M; Krayenbuehl HP J Am Coll Cardiol; 1991 Mar; 17(3):634-42. PubMed ID: 1993780 [TBL] [Abstract][Full Text] [Related]
56. [Evaluation of the effects of propranolol on hypertrophic cardiomyopathy by non-invasive technics]. Fang WH; Hu ZX; Wang SH; Li JR; Liu YS Zhonghua Xin Xue Guan Bing Za Zhi; 1980 Mar; 8(1):13-5. PubMed ID: 7192621 [No Abstract] [Full Text] [Related]
57. The natural history of hypertrophic cardiomyopathy. McKenna WJ; Goodwin JF Curr Probl Cardiol; 1981 Jul; 6(4):1-26. PubMed ID: 7026177 [No Abstract] [Full Text] [Related]
58. [Beta adrenergic receptors in patients with untreated and verapamil-treated hypertrophic cardiomyopathy]. Kölbel F; Krulík R; Slíva D; Hradec J; Aschermann M; Simper D; Schreiber V Sb Lek; 1988 Jul; 90(7):218-22. PubMed ID: 2851875 [No Abstract] [Full Text] [Related]
59. Effects of propranolol on response to exercise in hypertrophic obstructive cardiomyopathy. Edwards RH; Kristinsson A; Warrell DA; Goodwin JF Br Heart J; 1970 Mar; 32(2):219-25. PubMed ID: 5462284 [TBL] [Abstract][Full Text] [Related]